InVivo Biosystems provides essential services to help pharmaceutical, nutraceutical, biotechnology companies and academic research institutions worldwide accelerate the discovery and early-stage development of new compounds.
An expert in CRISPR genome editing, InVivo Biosystems creates custom genome-edited C. elegans and zebrafish models to enable aging, developmental and other disease studies. Our technologies bridge the gap between cells and mice, providing faster, cost-effective investigations that focus on proof-of-principle experiments for rapid go/no-go decision making.
Whether you need a screen of an antioxidant for its life promoting effects, or need to determine efficacy in a compound that boosts defective homeostatic mechanisms needed for longevity, we have customized our lifespan/healthspan assay for maximal effect detection. Our proprietary approach has been used by over a dozen labs and pharmas.
Compound Efficacy Assessment and Formulation Analysis. We can quickly and economically test a compound’s ability to extend lifespan and healthspan with large sample sizes (up to 120 million data points) of live animals in less than 5 months and get answers to the following questions:
We are a zebrafish CRO that offers multiple gene-editing services using CRISPR and Tol2 methods. Our services can significantly reduce your experiment design time and can be tailored to different experimental requirements. We offer a variety of service packages including fast, affordable Injection Mix to the comprehensive Full Build service to accommodate your level of expertise and budget.
Genome editing types include Knockout, Knock-in, MosSCI and Extrachromosomal Array. We offer a variety of services packages to fit the needs and budget of your lab from the fast, affordable Custom Injection Services to the comprehensive Full Build service packages, allowing you to customize the components you need to accomplish your gene editing goals.
Conduct pathogenicity assessment of variants in disease related genes.
We can perform expression and knock-out studies to identify and validate drug targets
and molecular mechanism of action (MMOA).
Our standard package includes:
We have found whole gene humanization can create a platform for highly translatable results in a model organism. We can conduct pathogenicity assessment of variants in disease related genes. Our standard process includes:
Our platform using whole gene humanization can create highly translatable results in a model organism.
InVivo Biosystems has not received any reviews.
InVivo Biosystems has not received any endorsements.